CytoGenix, Inc. Appoints Campbell Murray, MD to its Advisory Board
October 20 2010 - 10:06AM
Business Wire
CYTOGENIX, INC. (CYGX.PK-News) announced today that it has
appointed Campbell Murray, MD to its Board of Advisors.
Campbell Murray, MD: Campbell currently serves as a
director on the boards of Aileron Therapeutics, Akebia
Therapeutics, Alios BioPharma, BioRelix, Euthymics Bioscience,
ProCertus BioPharm and Tokai Pharmaceuticals and as an observer on
the board of MicroCHIPS and Tepha. Campbell, is a New Zealand
trained physician, Kauffman Fellow and holds an MBA from Harvard
Business School and an MPP (public policy) from the John F. Kennedy
School of Government where he was a Knox Fellow and Rotary
Ambassadorial Scholar.
Lex Cowsert, CEO of CytoGenix stated, “Having Dr. Murray join
the CytoGenix Board of Advisors adds significant benefit and
enhances our extremely talented team of Advisors, who all embrace
his admission to the Board of Advisors. Campbell's vast experience
is a tremendous asset which will help CytoGenix advance its product
line on a global platform, which can only add to shareholder
value.”
CytoGenix, Inc.
CytoGenix is a Nevada public corporation traded under the symbol
CYGX.PK. CytoGenix is a biotechnology company developing
biotechnology derived products for vaccines and therapeutic
applications for human, agricultural and veterinary markets. As
such, CytoGenix has access to a broad range of biological expertise
that can be leveraged to identify, evaluate, develop and
commercialize biologically based technologies for energy
production.
Safe Harbor Statement
The information contained in this news release, other than
historical information, consists of forward-looking statements
within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act. These statements may involve risks and
uncertainties that could cause actual results to differ materially
from those described in such statements. Although the Company
believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such
expectations will prove to have been correct. Important factors,
including general economic conditions, spending levels and other
factors could cause actual results to differ materially from the
Company's expectations.